Hudson Bay Capital Management LP Acquires Shares of 102,185 Disc Medicine, Inc. $IRON

Hudson Bay Capital Management LP bought a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 102,185 shares of the company’s stock, valued at approximately $6,752,000. Hudson Bay Capital Management LP owned approximately 0.27% of Disc Medicine as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IRON. Vanguard Group Inc. grew its holdings in shares of Disc Medicine by 3.7% in the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock valued at $95,688,000 after acquiring an additional 51,323 shares in the last quarter. JPMorgan Chase & Co. grew its position in Disc Medicine by 11.1% during the second quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after buying an additional 84,278 shares during the period. Geode Capital Management LLC increased its stake in shares of Disc Medicine by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 598,589 shares of the company’s stock worth $31,705,000 after purchasing an additional 26,605 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Disc Medicine by 257.1% during the 3rd quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock worth $33,040,000 after purchasing an additional 360,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Disc Medicine by 50.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 450,000 shares of the company’s stock valued at $23,832,000 after buying an additional 150,000 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Trading Down 1.7%

IRON stock opened at $58.17 on Friday. The company has a market capitalization of $2.20 billion, a PE ratio of -9.71 and a beta of 0.87. The company has a debt-to-equity ratio of 0.04, a quick ratio of 21.94 and a current ratio of 21.94. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $99.50. The company’s 50 day moving average price is $69.17 and its two-hundred day moving average price is $75.61.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The business had revenue of ($19.88) million during the quarter, compared to analysts’ expectations of $0.15 million. As a group, analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IRON shares. BMO Capital Markets lowered their price target on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 17th. Stifel Nicolaus decreased their target price on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Wedbush dropped their target price on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research report on Tuesday, February 17th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $104.80.

Insider Buying and Selling at Disc Medicine

In other news, insider Pamela Stephenson sold 5,531 shares of Disc Medicine stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $347,678.66. Following the transaction, the insider owned 80,998 shares in the company, valued at approximately $5,091,534.28. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John D. Quisel sold 13,264 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $833,775.04. Following the completion of the sale, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at approximately $14,210,383.04. This trade represents a 5.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 54,522 shares of company stock valued at $3,579,979. 3.64% of the stock is currently owned by insiders.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.